Stifel sees AtkinsRealis outperforming peers despite potential near-term headwinds

Investing.com -- AtkinsRealis shares have gained 0.4% year-to-date, while competitors Stantec and WSP Global have declined 12.9% and 17.6% respectively, according to a Stifel analysis.

The firm noted that AtkinsRealis trades at a premium 2027 price-to-earnings multiple of 18.5 times, compared to Stantec at 16.9 times and WSP Global at 15.4 times.

For the first quarter of 2026, Stifel's adjusted EBITDA estimate of $225 million sits 6% below the consensus figure of $238 million. However, the firm's full-year 2026 adjusted EBITDA projection of $1.184 billion aligns with market expectations.

Stifel warned that the company's Nuclear backlog could see temporary weakness until new contract awards materialize in the second half of 2026.

Despite the premium valuation and possible near-term volatility, Stifel indicated it would consider purchasing the stock on weakness, citing the company's strong Nuclear business outlook and underleveraged balance sheet as supporting factors.

You May Also Be Interested In

• Buffalo airport blames circuit fault, not shortage, for 3 flight delays
• Truist on agilon health Inc (AGL): 'From Stabilization to Value Creation'
• US automaker stocks fall after Trump announces Canada tariff hike